- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06314113
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection (EGCG-HPV)
Evaluation of Oral Epigallocatechin Gallate Treatment for Low-grade Cervical Lesions (L-SIL) Associated With Human Papilloma Virus (HPV) Infection
Study Overview
Status
Intervention / Treatment
Detailed Description
Human papilloma virus (HPV) infection is the most widespread infection worldwide among the sexually active population. Papillomaviruses are a very large and heterogeneous family of double-stranded DNA viruses (8kb). They have no envelope and have icosahedral symmetry. Their viral genome is divided into two regions defined as 1) early and 2) late. The early genes encode the early proteins E1, E2, E4, E5, E6, E7 necessary for viral DNA replication and cellular transformation. The late genes encode the late proteins L1, L2 which serve for the formation of the viral capsid. HPV viruses are classified based on their oncogenicity. Those at low risk are associated with proliferative lesions, generally benign, of the skin and mucous membranes. The clinical manifestations include common, flat and plantar warts, genital and flat condylomata acuminata which are the result of sexual transmission of the virus and which arise on the penis, anus, female genitalia, urethra, perianal area and straight. High-risk HPVs, on the other hand, are those that integrate into the host's genome and cause lesions that can evolve into carcinoma over time. However, it has recently been shown that even viruses normally defined as low risk can cause precancerous lesions in the case of tumors of the vulva, vagina, penis and anus. In 80% of cases the infection resolves spontaneously within two years, however in 20% of cases, the infection persists and causes the onset of lesions of varying degrees which over time can evolve into neck cancer of the uterus in women or penile cancer in men. In fact, if HPV is now recognized as the etiological agent of cervical cancer in 99.7% of cases, it is estimated that it is also responsible for 50% of penile tumors and 26-30% of cord tumors oral.
Persistence therefore represents an oncological risk factor for those who contract the infection, since if the infection persists for over a year, there is a high probability that the viral DNA integrates into the host's genome. Integration involves the constitutive expression of some viral oncoproteins (E6/E7) that block the activity of host tumor suppressor genes (p53/pRB). The blockade of tumor suppressors in turn stimulates an uncontrolled proliferation of lesions, which, due to a failure to activate the inhibitory regulatory processes of our organism, leads to tumor development.
In the case of lesions classified as "low grade" (L-SIL), the common practice is to check the patient after six months, while in the case of lesions classified as "high grade" (H-SIL), the therapeutic standard is represented by the surgical removal of these lesions. However, removal of the lesion does not guarantee total eradication of the infection, as the virus could persist in the adjacent healthy mucosa. Currently, there are no treatments against HPV infection, nor against the persistence of the virus. Various types of therapies are associated with primary (vaccination) and secondary (screening programs) prevention programs for the treatment of clinical manifestations induced by the virus, such as warts. Among the treatments that are used as normal clinical practice in the field of HPV infections, also for the treatment of warts, those based on epigallocatechin gallate (EGCG) represent a novelty that has been proven to be safe and effective.
Epigallocatechin gallate (EGCG), the main polyphenolic component of green tea, has antioxidant, anti-inflammatory and anticancer properties. Its action has also been extensively tested on cervical cancer lines, on which EGCG exerts an antiproliferative and pro-apoptotic action in a dose-dependent manner. A recent study demonstrated that EGCG increases the expression levels of p53 protein and reduces the levels of viral oncoproteins E6/E7. A randomized clinical trial has also highlighted how treatment with EGCG has a chemo-preventive action on the progression of lesions in HPV-positive women with lesions of various degrees, leading to a reduction in the degree of the lesions themselves.
Considering these elements, the study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Antonio Simone Laganà, M.D., Ph.D.
- Phone Number: +39 3296279579
- Email: antoniosimone.lagana@unipa.it
Study Locations
-
-
-
Palermo, Italy, 90127
- Recruiting
- "Paolo Giaccone" Hospital
-
Contact:
- Antonio Simone Laganà, M.D., Ph.D.
- Phone Number: +39 3296279579
- Email: antoniosimone.lagana@unipa.it
-
Sub-Investigator:
- Pietro Serra, M.D.
-
Sub-Investigator:
- Giuseppe Mascellino, M.D.
-
Sub-Investigator:
- Andrea Etrusco, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
Exclusion Criteria:
- Pregnancy
- Concomitant pathologies causing immunosuppression
- Concurrent Immunomodulatory therapies
- Hormone replacement therapy
- High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma
- Previous history of L-SIL or higher grade lesions ≥ 24 months
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Low-grade Cervical Lesions (L-SIL)
Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
|
Oral treatment with Epigallocatechin Gallate 200 mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence
Time Frame: After 6, 12, 18, and 24 months from the recruitment
|
Persistence of Low-grade Cervical Lesions (L-SIL), evaluated by pap smear
|
After 6, 12, 18, and 24 months from the recruitment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Antonio Simone Laganà, M.D., Ph.D., University of Palermo
- Study Chair: Andrea Etrusco, M.D., University of Palermo
- Study Chair: Pietro Serra, M.D., University of Palermo
- Study Chair: Giuseppe Mascellino, M.D., University of Palermo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Uterine Cervical Diseases
- Uterine Diseases
- Precancerous Conditions
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Uterine Cervical Dysplasia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Neuroprotective Agents
- Protective Agents
- Antioxidants
- Anticarcinogenic Agents
- Antimutagenic Agents
- Epigallocatechin gallate
Other Study ID Numbers
- EGCG-HPV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low-Grade Intraepithelial Neoplasia of Cervix
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingCervix Cancer | Cervix Intraepithelial Neoplasia Grade 3 | Cervix; Intraepithelial Neoplasia, Grade I | Cervix; Intraepithelial Neoplasia, Grade IIKenya
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
Saint Thomas Hospital, PanamaCompletedLSIL, Low-Grade Squamous Intraepithelial LesionsPanama
-
University of WashingtonNational Cancer Institute (NCI)CompletedCervical Carcinoma | Human Papillomavirus Infection | Health Status Unknown | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical Cancer | Atypical Squamous Cell of Undetermined Significance | Low Grade Cervical Squamous Intraepithelial NeoplasiaUnited States
-
Chinese University of Hong KongShenzhen Hospital of Southern Medical University; The Fifth Affiliated Hospital... and other collaboratorsRecruitingGastric Low Grade Intraepithelial NeoplasiaHong Kong
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
Hiantis SrlSciensano; Genefirst LTDCompletedNeoplasms | Neoplasms by Histologic Type | Carcinoma in Situ | Neoplasm Cervix | Cervical Intraepithelial Neoplasia Grade 2/3 | Carcinoma Cervix UterineItaly, Ireland, United Kingdom
-
Peking University People's HospitalHangzhou Newhorizon Health Technology Co., Ltd.; Hangzhou Mingze Medical Research... and other collaboratorsRecruitingCervical Cancer | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Human Papillomavirus Infection | Human Papilloma Virus | Adenocarcinoma in Situ | High-Grade Squamous Intraepithelial Lesions | Cervical Intraepithelial Neoplasia Grade II | Cervical Intraepithelial Neoplasia, Grade III | Atypical... and other conditionsChina
-
Khon Kaen UniversityTerminatedHuman Papillomavirus Clearance at 12 MonthsThailand
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
Clinical Trials on Epigallocatechin Gallate
-
Taipei City HospitalNational Yang Ming UniversityUnknownDiabetes Mellitus | HyperlipidemiaTaiwan
-
Catholic University of the Sacred HeartUnknownPrimary Open Angle Glaucoma | Ocular HypertensionItaly
-
Florian MichelGerman Federal Ministry of Education and ResearchCompletedLight Chain (AL) Amyloidosis | Cardiac InvolvementGermany
-
Parc de Salut MarCompleted
-
Purdue UniversitySociété des Produits Nestlé (SPN)CompletedObesity | Diabetes Mellitus, Type 2 | Appetitive BehaviorUnited States
-
Parc de Salut MarCompleted
-
Charite University, Berlin, GermanyCompletedRelapsing-remitting Multiple SclerosisGermany
-
Hal ChapmanNational Heart, Lung, and Blood Institute (NHLBI)CompletedIdiopathic Pulmonary FibrosisUnited States
-
Ministry of Health, Saudi ArabiaNot yet recruiting
-
Charite University, Berlin, GermanyCompletedDuchenne Muscular DystrophyGermany